Potent imidazole and triazole CB1 receptor antagonists related to SR141716.
Diarylimidazolecarboxamides and diaryltriazolecarboxamides related to SR141716 were synthesized and tested for binding to the human CB(1) receptor. Suitably substituted imidazoles are comparably potent to the clinical candidate, whereas the analogous triazoles are less so due to the absence of an additional substituent on the azole ring.
Departments of Medicinal Chemistry, Pharmacology and Molecular Biology, Neurocrine Biosciences Inc., 10555 Science Center Drive, San Diego, CA 92121, USA.
Brian
B
Dyck
Val S
VS
Goodfellow
Teresa
T
Phillips
Jonathan
J
Grey
Mustapha
M
Haddach
Martin
M
Rowbottom
Gregory S
GS
Naeve
Brock
B
Brown
John
J
Saunders
D007093:Imidazoles / Q000737:chemistry / Q000378:metabolism*; D010880:Piperidines / Q000737:chemistry / Q000378:metabolism*; D011485:Protein Binding; D011720:Pyrazoles / Q000737:chemistry / Q000378:metabolism*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D000077285:Rimonabant; D014230:Triazoles / Q000737:chemistry / Q000378:metabolism*
D007093:Imidazoles; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D014230:Triazoles; C029899:imidazole; D000077285:Rimonabant